An­oth­er Shkre­li-like drug price con­tro­ver­sy? Lea­di­ant finds it­self in the spot­light af­ter 500-fold price hike — FT

Mar­tin Shkre­li may be cool­ing his heels in a fed­er­al prison, but the phar­ma pric­ing strat­e­gy he pur­sued that got him in­to an in­tense na­tion­al con­tro­ver­sy ap­pears to be alive and well in Eu­rope this week.

The Fi­nan­cial Times con­cen­trat­ed its at­ten­tion over the week­end on the case of a drug called chen­odeoxy­cholic acid, or CD­CA. Lea­di­ant Bio­sciences, ear­li­er known as Sig­ma-Tau, gained con­trol of the cheap, old drug, once used to treat gall­stones, af­ter it had be­come rou­tine­ly used off-la­bel to treat a rare con­di­tion called cere­bro­tendi­nous xan­thomato­sis.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER